Oncolytic virus therapy in cancer: A current review

Table 3 Genetic modifications in the herpes simplex virus-1

Ref.	Virus	Updates	Aim
Liu et al[61]	T-VEC	Insertion of GM-CSF and deletion of γ34.5, US12	Increase lytic activity and antitumor immunity
Ushijima et al[233]	HF10	Insertion of UL53, UL54 and deletionof UL43, UL49.5, UL55, UL56, LAT	Reduce neurovirulence and increase immunogenicity
Ebright et al[234]	NV1020	Incorporation of the HSV-1 TK gene and deletion of α0, α4, γ34.5, UL56, UL24	Reduce neurovirulence and provide susceptibility to antiviral chemotherapy
MacKie et al[235]	HSV 1716	Incorporation of γ34.5	Reduce neurovirulence
Mineta et al[236]	G207	Insertion of lacZ and deletion of γ34.5	Avoid ribonucleotide reductase encoding and reduce neurovirulence

GM-CSF: Granulocyte-macrophage colony-stimulating factor; HSV-1: Herpes simplex virus 1; LAT: Latency-associated transcript; T-VEC: Talimogene laherparepvec; TK: Thymidine kinase.